VP-315 abscopal data reshapes BCC multifocal treatment calculus

Phase 2 data from Verrica Pharmaceuticals on VP-315 (ruxotemitide) introduce a clinically significant variable for R&D and regulatory teams tracking intratumoral immunotherapy: evidence of tumour regression in lesions that received no direct treatment, a pattern consistent with an abscopal effect in basal cell carcinoma.

Verrica's VP-315 shows abscopal-like regression in untreated BCC lesions

In an open-label Phase 2 trial, subjects received intratumoral VP-315 injections of less than 8 mg into up to two treated lesions. Up to three non-treated lesions per subject were monitored over 12 weeks, with changes assessed histologically after excision. Across treated lesions, average tumour size reduction reached 86%; regression was also observed in non-treated lesions, suggesting systemic immune activation beyond the injection site.

The mechanism proposed is immunogenic cell death: VP-315, a first-in-class oncolytic chemotherapeutic peptide, is designed to release a broad spectrum of tumour antigens upon intratumoral administration, priming T-cell responses within the tumour microenvironment. Peripheral anticancer activity in non-target lesions, if confirmed in pivotal testing, would distinguish VP-315 from conventional localised ablative approaches and carry direct implications for labelling strategy.

The regulatory read for CMC and clinical teams building the BCC dossier

For regulatory affairs leads, abscopal-effect data in a Phase 2 setting represent a hypothesis, not a confirmed mechanism of action, and the evidentiary bar for pivotal submission will be considerably higher. The current dataset is derived from an open-label design with histological assessment of non-treated lesions at excision; blinded, controlled confirmation of the effect will be a prerequisite for any MOA claim in a future NDA or BLA package.

The clinical relevance is nonetheless material for programme planning. Approximately one-third of BCC patients develop additional primary tumours over their lifetime, and multifocal disease represents a documented unmet need. If VP-315's systemic immune activation holds in larger cohorts, CMC teams will need to account for a broader patient population in trial design, endpoint selection, and ultimately in the benefit-risk framework presented to FDA.

Verrica holds an exclusive worldwide licence for VP-315 across several dermatologic oncology indications, with basal cell and squamous cell carcinomas as lead development targets. The neoadjuvant framing introduced by the company's Chief Medical Officer also signals a potential positioning strategy that could intersect with surgical standard-of-care pathways, a nuance that health authority interactions will need to address early.

SID poster and pivotal trial design are the near-term checkpoints

The Phase 2 poster, designated LB1190 under the Non-Melanoma Cancers and UV Biology/Injury category, is scheduled for presentation on 15 May 2026 at the SID Annual Meeting in Chicago. The full dataset, including histological methodology and non-treated lesion response rates, will be available at that session and will inform the design parameters for any subsequent pivotal study.

Confirmation of the abscopal signal in a controlled, adequately powered pivotal trial remains the critical milestone before the effect can anchor a regulatory submission or inform prescribing guidance for multifocal BCC.